English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Methods 10 children aged 4 – 12 years with anterior uveitis associated with JIA were treated by Abatacept in standard infusions pattern and doses. Indication for using Abataceptwas ineffectiveness of standard therapy of arthritis and/or uveitis. 6 patients were suffering from polyarticular variants, 4 – oligoarticular JIA. Abatacept was combined with Methotrexate in 9, Sulfasalazin in 1 and lowdose steroids in 4 children. 3 patients were switched to Abatacept from Infliximab due to non-efficacy, 7 received abatacept as a first line biologic. 9 patients had bilateral eye involvement. At the administration of Abatacept severe inflammation was seen in 1, moderate in 7, mild in 2 of the cases. Follow up period ranged from 3 to 11 month (mean 7.6). The main outcome measure was the degree of inflammation.

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis